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A B S T R A C T  
In December 2019 a series of acute atypical respiratory disease occurred in Wuhan, China. The first 
clusters of cases were identified in association with the South China Seafood Market. In subsequent 
investigations it was found to be a novel coronavirus. It is suggested to have zoonotic origin. On 
December 31st 2019, China notified the outbreak to the World Health Organization. During the 
New Year, the massive migration of Chinese fuelled the epidemic. Cases in other provinces of China 
and other countries (South Korea, Thailand and Japan in quick succession) were reported in people 
who were returning from Wuhan. On 11 February, on the basis of existing rules on taxonomy the 
virus was names as SARS-CoV-2. SARS-CoV-2 belongs to the family of coronaviruses. It is a 
positive-sense single-stranded RNA (+ssRNA) virus. It has a single linear RNA segment. On the 
same day WHO announced the new name for the disease i.e. Coronavirus disease 2019 (COVID-19). 
The WHO and the US Centers for Disease Control and Prevention (CDC) say it is primarily spread 
directly due to close contact between people through small droplets produced during coughing, 
sneezing or talking within a range of about 1-3 meters. It may even transmit through indirect contact 
via fomites. While there are concerns it may spread by feces, this risk is believed to be low. Soon, the 
number of cases started increasing exponentially and on March 12, 2020 WHO announced COVID-
19 a pandemic. COVID-19 has been impacting a large number of people worldwide, being reported 
in approximately 200 countries and territories. It was identified that Angiotensin converting enzyme 2 
(ACE2) act as a functional receptor for SARS-CoV-2. The pathophysiology of COVID-19 follows 
sex differences, age differences, race differences in as well as underlying disease conditions i.e. 
comorbidities aggravated the severity of this disease.  The most common symptoms being reported 
are fever, dry cough or chest tightness, and dyspnoea. It is now widely recognized that respiratory 
symptoms of COVID-19 are extremely heterogeneous, ranging from minimal symptoms to 
significant hypoxia with ARDS. Diagnosis is done with the help of history, clinical signs and 
serological testing. Real-time reverse transcription polymerase chain reaction (rRT-PCR) is 
considered the standard method of testing. Several have been tested in clinical trials but none of them 
have been proven to be a definite therapy yet. The evolution of the current outbreak has seen 
extraordinary measures put in place to control transmission, including the ‘shut-down’ and 
‘quarantine’. Researchers are trying to develop a vaccine against SARS-CoV-2 but at present, no 
vaccine is available. One should strictly follow all the preventive measures as directed by WHO and 
CDC and along with this, one should boost up its natural immunity to lessen the chances of getting 
infection.  
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1 Introduction 
Health authorities identified a series of acute atypical respiratory disease occurred in Wuhan, 
China with unknown etiology during December 2019, which rapidly spread from Wuhan to other areas. 
In subsequent investigations, it was discovered that a novel coronavirus was responsible for this. The 
outbreak of SARS-CoV-2 was considered to have originally started via a zoonotic transmission associated 
with the seafood market, later it was recognized that human to human transmission played a major role in 
the subsequent outbreak caused by this virus (Li et al., 2020). Initially WHO named the virus causing this 
illness as Novel Coronavirus, but on 11 February 2020, the International Committee on Taxonomy of 
Viruses (ICTV) identified 2019-nCoV as a strain of severe acute respiratory syndrome-related coronavirus 
and named as SARS-CoV-2, because according to existing rules that are based on five conserved 
sequences of nucleic acids that determine hierarchical relationships among coronaviruses ,the differences 
between what was then called 2019-nCoV and the virus strain from the 2003 SARS outbreak were not 
sufficient enough to make novel corona virus and SARS-CoV separate viral species. On the same day i.e. 
February 11, 2020 WHO announced a name for the new coronavirus disease: COVID- 19 and on March 
12, 2020 a pandemic. COVID-19 has been impacting a large number of people worldwide, being reported 
in approximately 200 countries and territories (Zheng et al., 2020; Zhang et. al., 2020). SARS-CoV-2 virus 
primarily affects the respiratory system, although other organ systems are also involved. It is now widely 
recognized that respiratory symptoms of COVID-19 are extremely heterogeneous, ranging from minimal 
symptoms to significant hypoxia with ARDS (Yuki et. al., 2020). Current medical management is largely 
supportive with no targeted therapy available. Several drugs including lopinavir-ritonavir, remdesivir, 
hydroxychloroquine, and azithromycin have been tested in clinical trials (Cao et. al., 2020; Gautret et. al., 
2020; Zhou et. al., 2020) but none of them have been proven to be a definite therapy as yet. The evolution 
of the current outbreak has seen extraordinary measures put in place to control transmission, including 
the ‘shut-down’ and ‘quarantine’. Preventive measures play a major role in prevention of this disease. 
Researchers are trying to develop a vaccine against SARS-CoV-2 but at present, no vaccine is available. 
2 Origin and spread 
In early December 2019, health authorities identified at Wuhan. The first clusters of cases were 
reported at the South China Seafood Market, where a large range of live or freshly slaughtered animals 
put on sale including poultry, bats, and snakes (Lake, 2020).  On December 31st 2019, China notified the 
outbreak to the World Health Organization (“19” in COVID-19 represents its notifying year i.e. 2019) 
thereafter on 1st January the Huanan sea food market was closed. The number of cases started increasing 
exponentially, many of which did not have exposure to the live animal market, suggestive of the fact that 
human-to-human transmission was occurring (Huang et al., 2020) which got confirmed later on (Chen et 
al., 2020). The first fatal case was reported on 11th Jan 2020 (WHO, 2020). During the New Year, the 
massive migration of Chinese fuelled the epidemic. In China, Cases continued to increase exponentially 
and modelling studies reported an epidemic doubling time of 1.8 d (Li, 2020).  Cases in other provinces 
of China and other countries (South Korea, Thailand and Japan in quick succession) were reported in 
people who were returning from Wuhan. Soon the city was locked down by government. Due to its 
ability to transmit from human to human by direct and indirect methods, soon cases started coming up in 
various countries like Italy, Europe, South Korea, India and other countries. Within these countries also 
the cases started increasing exponentially. On March 12, 2020 WHO announced COVID-19 a pandemic 
and disease of major public health concern with expected incubation period of COVID-19 is 2-14 days 
(WHO, 2020). 
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3 Virology 
The SARS-CoV-2 belongs to the family of coronaviruses. It is a positive-sense single-stranded 
RNA (+ssRNA) virus. It has a single linear RNA segment. Coronaviruses are a broad family of viruses. 
Illnesses caused by coronaviruses ranges from the common cold to more severe diseases such as Middle 
East respiratory syndrome (MERS) and SARS. It is the seventh known coronavirus to infect people, after 
229E, NL63, OC43, HKU1, MERS-CoV, and SARS-CoV (Zhu et al., 2020) SARS-CoV-2 is closely 
related to the original SARS-CoV. Like the SARS-related coronavirus strain involved in the 2003 SARS 
outbreak, SARS-CoV-2 is a member of the subgenus Sarbecovirus (beta-CoV lineage B) (WHO, 2020). 
The length of RNA sequence of SARS-CoV-2 is approximately 30,000 bases. The SARS-CoV-2 is unique 
among known betacoronaviruses in its incorporation of a polybasic cleavage site, a characteristic known 
to increase pathogenicity and transmissibility in other viruses (Walls et al., 2020; Coutard et al., 2020). On 
11 February 2020, the International Committee on Taxonomy of Viruses (ICTV) identified 2019-nCoV as 
a strain of Severe acute respiratory syndrome-related coronavirus and named it SARS-CoV-2 because 
according to existing rules that are based on five conserved sequences of nucleic acids that determine 
hierarchical relationships among coronaviruses, the differences between what was then called 2019-nCoV 
and the virus strain from the 2003 SARS outbreak were not sufficient enough to make novel corona virus 
and SARS-CoV separate viral species (Gorbalenya et al., 2020). Diameter of SARS-CoV-2 virion is 
approximately 50–200 nanometres (Chen et al., 2020). The SARS-CoV-2 has four structural proteins, 
known as the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins like other 
coronaviruses. The S, E, and M proteins together create the viral envelope of the SARS-CoV-2 and N 
protein holds the RNA genome. The spike protein is responsible for allowing the virus to attach and fuse 
with the membrane of a host cell (Wu et al., 2020). Protein modeling experiments on the spike protein of 
the virus suggested that SARS-CoV-2 has affinity to bind with the receptor angiotensin converting 
enzyme 2 (ACE2) on human cells and thereby enter inside the body (Chen et. al., 2020; Letko et al., 2020; 
Letko and Munster, 2020; Xu et al., 2020). For entry of SARS-CoV-2, initial spike protein priming 
by transmembrane protease, serine 2 (TMPRSS2) is essential (Hoffman et al., 2020).  After attachment of 
SARS-CoV-2 virion to a target cell, the spike protein of the virus is cleaved by cell's protease TMPRSS2 
thereby exposing a fusion peptide.  The RNA of the virion is then released into the cell and the cell is 
forced to produce and disseminate copies of the virus, which infect more cells (Hoffman et. al., 2020; Ou 
et. al., 2020). 
4 Transmission 
During this pandemic, human-to-human transmission of SARS-CoV-2 has been confirmed 
(Chan et al., 2020). The WHO and the US Centers for Disease Control and Prevention (CDC) said, it is 
primarily spreading directly due to close contact between people through small droplets produced during 
coughing, sneezing or talking within a range of about 1-3 meters. Those released droplets can be possible 
inhaled into the lungs by the people who are nearby.  Even some medical procedures such 
as intubation and cardiopulmonary resuscitation (CPR) may result in an airborne spread by causing 
respiratory secretions to be aerosolized. The serial interval for COVID-19 virus is estimated to be 5-6 
days (WHO, 2020; CDC, 2020).   
It may even transmit through indirect contact via fomites, when a person sneezes or coughs the 
droplets fall on the nearby surfaces and it may get transmitted when someone touches that contaminated 
surface and then touches his eyes, nose or mouth. The virus survives for hours to days on surfaces. 
Specifically, the virus was found to be viable for one day on cardboard, for up to three days on plastic and 
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stainless steel and for up to four hours on copper (van Doremalen et al., 2020). This however, varies 
based on the humidity and temperature. 
Viral RNA has also been found in stool samples from infected people (Holshue et al., 2020). 
There are concerns it may spread by feces, the risk of is transmission by faeces is believed to be low 
(WHO, 2020). There is some evidence of human-to-animal transmission of SARS-CoV-2 also. In Europe, 
some house cats living with COVID-19 positive owners have also tested positive for SARS-CoV-2 
infection (OIE, 2020). Recently, a tiger at the Bronx Zoo was found to be infected with SARS-CoV-2 
(Goldstein and Joseph, 2020). 
 It has been indicated that the pharynx reaches peak viral load approximately four days after 
infection (Wölfel et al., 2020; Kupferschmidt, 2020). The virus is most contagious when people are 
symptomatic, though spread is also possible before symptoms emerge and from those asymptomatic 
people who never developed symptoms. On 1 February 2020, the WHO indicated that transmission from 
asymptomatic cases is likely not a major cause of transmission (WHO, 2020).  However, an 
epidemiological model of the beginning of the outbreak in Wuhan, China suggested that among 
documented infections pre-symptomatic shedding of virus may be typical and people with subclinical 
disease may have served as major source of infection to majority of infected people (Li et al., 2020). 
5 Reservoir 
The anamnesis of first known infection from the SARS-CoV-2 strain, discovered in Wuhan, 
China (Zhou et al., 2020) indicated, original source of viral transmission to humans as well as whether the 
viral strain became pathogenic before or after the spillover event is imprecise till now (van Doremalen et 
al., 2020). The first cluster of cases were identified in association with the South China Seafood Market, a 
‘wet’ market at which a large range of live or freshly slaughtered animals were sold including poultry, bats, 
and snakes (Lake, 2020).  It has been suggested that the strain might have originated from the market 
itself (Wölfel et al., 2020). However, other research indicates that visitors may have introduced the virus to 
the market, which then facilitated rapid expansion of the infections due to close contact of people there 
(Cyranoski, 2020). Initially bats were considered the most likely natural reservoir of SARS-CoV-2 (WHO). 
Samples were taken from Rhinolophus sinicus and analysis of some viral nucleic acid sequences showed a 
resemblance of 80% to SARS-CoV-2 (Benvenuto, et al., 2020). A study showed that viral nucleic acid 
sequence in a sample taken from Rhinolophus affinis, collected in Yunnan province and designated RaTG13, 
has a 96% resemblance to SARS-CoV-2 (Zhou et al., 2020). In SARS outbreak also many SARS- like bat 
coronaviruses were discovered, mostly originating from genus Rhinolophus only but there are some 
differences between the bat coronavirus and SARS-CoV-2 which suggest a possibility that humans were 
infected via an intermediate host (Cyranoski, 2020). The virus genome has a novel lineage for almost half 
of its genome, with no close genetic relationships to those of its subgenus, sarbecovirus (Paraskevis et al., 
2020).  On 7 February 2020, researchers from Guangzhou announced that they had discovered a pangolin 
sample in which viral nucleic acid sequence is "99% identical" to SARS-CoV-2 (Cyranoski et al., 2020). 
The results clarified that with a difference of only one amino acid, the receptor-binding domain of the S 
protein is almost identical to that of 2019-nCoV (Xiao et al., 2020). Since pangolins are critically 
endangered hence they are protected under government law, but their trafficking for use in traditional 
Chinese medicine and to be eaten as luxury food remains common. So, it is a possibility that transmission 
of SARS-CoV-2 had occurred due to trade of pangolins across the countries. Geneticists and 
microbiologists in Texas have separately found the evidence that reassortment has taken place in 
coronaviruses which suggests the involvement of pangolins in the origin of SARS-CoV-2 (Wong et al., 
2020). However, only at most 92% of homology has been seen in genome of pangolin coronaviruses 
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found till date and SARS-CoV-2, making them less similar than RaTG13 to SARS-CoV-2 (Zhang et al., 
2020). This is inadequate to prove pangolins to be the intermediate host because in comparison to it, the 
SARS virus responsible for the 2003 outbreak shared 99.8% of its genome with a known civet 
coronavirus (Cyranoski et al., 2020). Previously a metagenomic study was published in 2019 which 
revealed that among a sample of Sunda pangolins, SARS-CoV: causative agent of SARS outbreak, 2003, 
was the most widely distributed coronavirus (Liu et al., 2019). It also strengthens the possibility that 
pangolins serve as an intermediate host in transfer of SARS-CoV-2. 
6 Pathophysiology 
The expected incubation period of COVID-19 is 2-14 days with hyperinflammation, renin-
angiotensin-aldosterone system imbalance, and a particular form of vasculopathy, thrombotic 
microangiopathy, and intravascular coagulopathy. SARS-CoV-2 impairs innate and adaptive antiviral 
responses, triggers hyperinflammation, and deranges the renin-angiotensin-aldosterone system (RAAS), 
all culminating to promote detrimental hypercoagulability and immunothrombosis. The SARS-CoV-1 and 
SARS-CoV-2 share up to 85% genomic identity, and both utilize the same primary human host receptor, 
angiotensin converting enzyme 2 (ACE2), to enter target cells (Zhou et al., 2020). 
6.1 Receptor bounded entry 
It was identified that Angiotensin converting enzyme 2 (ACE2) act as a functional receptor for 
SARS-CoV (Li et. al., 2003). Structural and functional analysis of SARS-CoV-2 showed that the spike for 
SARSCoV-2 also bound to ACE2 (Chen et. al., 2020; Letko et. al., 2020). In a study it was found that 
ACE2 expression was high in lung, heart, ileum, kidney and bladder (Zou et. al., 2020).  
6.2 Respiratory System 
It was found that ACE2 receptors were highly expressed on lung epithelial cells.  Whether or not 
SARS CoV- 2 binds to an additional target is not clear and needs further investigation. Following the 
binding of SARSCoV-2 to the host protein, the spike protein undergoes protease cleavage (Ou et. al., 
2020). Earlier, a two-step sequential protease cleavage to activate spike protein of SARS-CoV and MERS-
CoV was proposed as a model, consisting of cleavage at the S1/S2 cleavage site for priming and a 
cleavage for activation at the S’2 site, a position adjacent to a fusion peptide within the S2 subunit 
(Belouzard et. al., 2009) but whether the cleavage in SARS-CoV-2 follows the same pattern is still to be 
elucidate. After the cleavage at the S1/S2 cleavage site, S1 and S2 subunits remain non-covalently bound 
and the distal S1 subunit contributes to the stabilization of the membrane anchored S2 subunit at the 
prefusion state (Walls et. al., 2020). Subsequent cleavage at the S’2 site presumably activates the spike for 
membrane fusion via irreversible, conformational changes. The coronavirus spike is unusual among 
viruses because a range of different proteases can cleave and activate it (Belouzard et. al., 2012). SARS-
CoV-2 has some unique characteristics among coronaviruses like the existence of furin cleavage site 
(“RPPA” sequence) at the S1/S2 site. The S1/S2 site of SARSCoV-2 is entirely subjected to cleavage 
during biosynthesis in a drastic contrast to SARS-CoV spike, which is incorporated into assembly without 
cleavage (Walls et al., 2020). Although the S1/S2 site was also subjected to cleavage by other proteases 
such as transmembrane protease serine 2 (TMPRSS2) and cathepsin L, the ubiquitous expression of furin 
likely makes this virus very pathogenic (Hoffman et. al., 2020; Ou et. al., 2020).  
6.3 Digestive system 
The receptors for SARS-CoV-2 virus are also present in gastrointestinal tract. The ACE2 is 
abundantly expressed in endothelial cells and enterocytes of the small intestine as well as the glandular 
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cells of gastric, duodenal and rectal epithelium (Hamming et al., 2020; Gu et al., 2020) which is probably 
responsible for gastro-intestinal signs in humans. 
6.4 Nervous system 
The ACE2 is also expressed in the brain, it is particularly present in the brain stem and in the 
regions responsible for cardiovascular function regulation including paraventricular nucleus (PVN), 
subfornical organ, rostral ventrolateral medulla and nucleus of the tractus solitarius (NTS); expression of 
ACE2 was found in both neurones as well as glia. But we cannot exclude the possibility of non-ACE2 
pathways for virus infection of neural cells this is because marked penetration of coronavirus into the 
liver which is an organ with lower levels of ACE 2 compared to the CNS, supports the assumption that 
the cell entry routes can vary and suggested that he neuroinvasive potential of SARSCoV2 may play a 
role in the respiratory failure of COVID19 patients (Li et al., 2020). 
6.5 Vascular system 
Since, vascular endothelium actively expresses ACE2 hence SARS-CoV-2 is capable of directly 
infecting these cells (Nicin et al., 2020). A recently published histopathology report showed endothelial 
cell infection and inflammation of endothelial cells i.e. endothelitis in 3 patients with COVID-19 (Varga et 
al., 2020). Along with direct cytopathic effects it causes hyperinflammation which leads to local and 
systemic endothelial injury and dysfunction, this results in increased vascular permeability, excess 
thrombin generation and inhibition of fibrinolysis (Frantzeskaki et al., 2017). It is seen that plasma levels 
of TF and PAI-1 are significantly elevated in patients with non-specific ARDS as compared to non-
ARDS patients, leading to a lung coagulopathy driven by increased thrombin generation as well as 
bronchoalveolar depression of fibrinolysis (Ozolina et al., 2016; Glas et al., 2013). Moreover, there is 
increased risk of severe and fatal COVID-19 in patients with co-morbidities such as hypertension, 
diabetes and obesity may in part be due to the underlying endothelial dysfunction, which is common in 
these conditions. 
Overall, as hyperinflammation progresses systematically, it may culminate in widespread 
immunothrombosis, contributing to organ dysfunction. The hypercoagulable state may potentially be 
further enhanced by other clinical factors including hypoxemia which is secondary to ALI/ARDS, 
hyperthermia and/or hypovolemia which is secondary to gastrointestinal fluid loss and/or negative fluid 
balance in the ARDS treatment Protocol (Meyer et al., 2013). There is disseminated intravascular 
coagulation (DIC) and leukoerythroblastic reaction seen in patients of COVID-19 (Mitra, et al., 2020; 
Lillicrap et al., 2020). 
6.6 Renin-Angiotensin-Aldosterone-System (RAAS) Derangement in COVID-19 
The RAAS dysfunction plays a significant role in the pathophysiology of general acute respiratory 
distress syndrome (ARDS) (Vrigkou et al., 2017; Zhang and Baker, 2017). The ACE2, which is host cell 
receptor of SARS-CoV-2, is a major component of RAAS (Zhou et al., 2020). Thus, we hypothesize that 
RAAS aberrations contribute significantly to the likelihood of developing severe COVID-19 symptoms 
(Sanchis-Gomar et al., 2020). The ACE converts angiotensin I (AngI) to angiotensin II (AngII), while 
ACE2 converts AngII to angiotensin 1-7 (Ang1-7). Thereafter, AngII binds with AngII receptor type 1 
(AT1) and exerts pro-oxidative, vasoconstrictive, pro-inflammatory and even fibrotic effects. In contrary, 
Ang1-7 binds to the Mas receptor (MasR) and mediates anti-oxidative, vasodilatory, and anti-
inflammatory effects (Guan et al., 2020). This suggests that the binding of SARS-CoV-2 to ACE2 
attenuates ACE2 activity via internalization, thereby disturbing the ACE/ACE2 balance to a state which 
is predominated by high levels of AngII, which causes pulmonary vasoconstriction, oxidative, 
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inflammatory and fibrotic organ damage which is the ultimate cause behind progressing towards 
ALI/ARDS. The RAAS system is intrinsically linked to the coagulation cascade and may exacerbate the 
processes of immunothrombosis, further driving microthrombi formation in COVID-19. First, AngII 
induces PAI-1 expression by endothelial cells via the AT1 receptor, contributing to a PAI-1/tPA 
imbalance and a hypercoagulable state (Nakamura et al., 2000; Vaughan et al., 1995). This may explain why 
unresolved fibrin deposits are observed in the alveoli of patients with general ARDS, a feature that has 
also been observed in lungs of both SARS and COVID-19 victims (Yao et al., 2020). 
Secondly, ACE metabolizes bradykinin. Bradykinin can stimulate vasodilation and release of 
tissue plasminogen activator (tPA) from endothelial cells (Brown et al., 1999). It can be assumed that an 
inflammatory response to COVID-19 would lead to increased bradykinin production (and hence 
increased tPA expression). However, elevated AngII would lead to increased aldosterone that may further 
enhance ACE activity, which converts bradykinin to inactive peptides, blunting the bradykinin-mediated 
tPA increase (Stoll, 2020). Based on observations of hypokalemia, a hyperaldosterone state is suspected in 
cases of severe COVID- 19 (Lippi and Plebani, 2020). Moreover, aldosterone has also been shown to 
directly increase PAI-1 expression, especially in renal tissue (Brown et al., 2000; Ma et al., 2006). Hence, 
while bradykinin (and hence tPA) may be increased, the increased ACE, AngII and aldosterone (and 
hence PAI-1) is likely to be of greater magnitude, leading to a decreased tPA to PAI-1 ratio, promoting 
hypofibrinolysis. In addition to the microthrombi, this imbalance may lead to poor resolution of alveolar 
lesions and explain the significant degree of fibrosis observed in COVID-19 patients (Yao et al., 2020). 
ACE inhibitors (ACEi) have been shown to improve endothelial function and have been suggested to be 
associated with less severe COVID- 19 disease (Sanchis-Gomar et al., 2020). This suggests that 
hyperinflammation and detrimental immunothrombosis may be central to the pathophysiology of 
COVID-19. Platelet hyper-reactivity, hypofibrinolysis, complements over-activation, hypercoagulability 
and RAAS derangement in the presence of underlying inflammatory-induced endothelial dysfunction 
likely lead to a state of COVID-induced coagulopathy. 
7 Immunopathology 
The COVID-19 is associated with CD4+ and CD8+ T-cell lymphopenia, which may result from 
a combination of virus-induced direct cytopathic effects, as well as enhanced T-cell apoptosis due to a 
dysregulated cytokine milieu (Wang et. al., 2020; Tan et. al., 2020). Furthermore, CD4+ T-lymphopenia 
may impair the adaptive antiviral response through inadequate T-cell help to virus-specific CD8+ 
cytotoxic T-cells and B-cells. 
8 Sex differences 
Investigation of data obtained from China and Italy, it becomes clear that males are 
approximately 64-71% of total deceased COVID-19 patients (China CDC; Italian National Institute of 
Health, 2020) as well as in Europe also, out of total people infected with COVID-19, 57% were men; out 
of those who were infected with COVID-19 who also died, 72% were men (WHO, 2020). It has largely 
been attributed to gender differences in some risk factors (Wenham et al., 2020). However, 
immunobiological sex differences may also contribute. The TLR7 gene is located on chromosome X, and 
escapes X chromosome inactivation, resulting in enhanced expression in females (Souyris et al., 2020). 
more pronounced IFN-α release from cells is induced by TLR7 agonists in females (Berghöfer et al., 2006) 
and following TLR7 agonism, type I IFN release is enhanced by estradiol (Seillet et al., 2012). The Biallelic 
TLR7 expression and subsequent estradiol signaling may potentially render females less prone to the viral 
type I IFN antagonism, which may lead to a more substantial type I IFN response in early stages of 
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disease. This may potentially improve the initial antiviral response and prevent the subsequent aberrant 
hyperinflammation, in part explaining increased disease severity in males. However, this theory requires 
additional studies. 
9 Age group differences 
Usually infants and young children are at high risk for admission to hospitals due to respiratory 
tract infection with viruses as influenza virus and respiratory syncytial virus. In contrast, pediatric 
COVID-19 patients have relatively milder symptoms in general compared to elder patients. The exact 
reason for this difference between children and adults remains elusive. But because a recent report 
suggested that there is correlation between the amount of viral loads and the severity of COVID-19 (Liu 
et al., 2020) so it is a possibility that the children may have less virus loads even if they get COVID-19. In 
support of this a couple of hypotheses can be considered.  
The first possibility is that the expression level of ACE2 may differ between adults and children. 
A previous study showed that ACE2 was more abundantly expressed on well-differentiated ciliated 
epithelial cells (Hamming et al., 2004). Human lung and epithelial cells continue to develop following the 
birth hence ACE2 expression may be lower in pediatric population.  
The second possibility is that children have a qualitatively different response to the SARS-CoV-2 
virus in comparison to adults. With ageing, continuous antigen stimulation and thymic involution leads to 
a shift in T cell subset distribution from naïve T cells to central memory T cells, effector T cells and 
effector memory T cells (Saule et al., 2006). This process is accompanied by the loss of expression of co-
stimulatory molecules such as CD27 and CD28, with increased susceptibility to infections (Li et al., 2019). 
Whether the appearance of pathological T cells in adult patients with severe COVID-19 diseases is due to 
the compensation for this fundamental aging process or not is unclear. At the early stage after birth, 
CD4+ T cells are impaired in production of Th1 associated proinflammatory cytokines and shift toward 
Th2 (Connors et al., 2016). CD8+ T cells reduced expression of cytotoxic and inflammatory mediators. 
However, less killing ability by T cells at early stage after birth may explain susceptibility to SARS-CoV-2 
in infants. But the study comparing aged and young macaques infected with SARS-CoV showed that aged 
macaques had more robust proinflammatory responses with worse lung pathology than young ones 
(Smits et al., 2010).  
A similar result was reported using aged and young mice infected with SARS-CoV (Roberts et al., 
2007). So similarly, it is expected that pro-inflammatory responses make this disease severe in adults as 
compared to infants and ageing is associated with increasing proinflammatory cytokines that govern 
neutrophil functions and have been correlated with the severity of ARDS. Severe COVID-19 infection is 
characterized by a massive proinflammatory response or cytokine storm that results in ARDS and multi -
organ dysfunction (MODS).  
The third possibility is that the simultaneous presence of other viruses in the mucosa lungs and 
airways, common in young children, can let SARS-CoV-2 virus compete with them and limit its growth 
(Nickbakhsh et al., 2019). It is possible that a combination of these possibilities helps in understanding 
why children in general are less susceptible to severe COVID-19. 
10 Racial differences 
It has been observed that during the outbreak of COVID-19 in the US, a greater proportion of 
deaths occurred among African Americans (van Dorn et al., 2020). This is supposed to be because of their 
sub-standard living which prevents African Americans to follow social distancing because of crowded 
housing. As well as most of the African Americans are involved in ‘essential occupations’ like health care 
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workers and public transit services so they have to go door to door for their work. Most of them have 
high prevalence of underlying disease conditions like diabetes, asthma, cardiovascular diseases etc. So they 
are more prone to the infection. However, to know the exact cause behind this, further studies are 
required (Adams et al., 2020). 
11 Underlying disease conditions 
The pandemic, COVID-19 appears to be more severe in patients with underlying disease 
conditions like hypertension, cardiovascular disease, and diabetes (Guan et al., 2020). These disorders are 
associated with reduced baseline levels of ACE2 expression, which makes the people with these 
underlying disease conditions more susceptible to SARS-CoV-2 mediated ACE/ACE2 imbalance (Tikellis 
et al., 2020). 
12 Signs and symptoms 
The clinical features of COVID-19 are varied, ranging from asymptomatic state to acute 
respiratory distress syndrome and multi organ dysfunction. In a subset of patients, by the end of the first 
week the disease can progress to pneumonia, respiratory failure and death. The most common symptoms 
being reported are fever, dry cough or chest tightness and dyspnoea. Thus, they are indistinguishable 
from other respiratory infections. Conjunctivitis, throat, headache, fatigue, myalgia, diarrhea and loss of 
sense of smell and taste have also been described (WHO, 2020). Most reported cases experience a mild 
illness course. In addition, headache, dizziness, generalized weakness; vomiting and diarrhea were 
observed in some patients (Rodríguez-Morales et al., 2020). It is now widely recognized that respiratory 
symptoms of COVID-19 are extremely heterogeneous, ranging from minimal symptoms to significant 
hypoxia with ARDS (Yuki et. al., 2020). Usually without needing hospital treatment, most people (about 
80%) recover from this disease. Around 1 out of every 5 people who gets COVID-19 becomes seriously 
ill and develops difficulty breathing (WHO, 2020). 
Observations, case studies and some case series suggest COVID-19 can affect the feet or lower 
limb (Mazzotta and Troccoli, 2020; Fernandez-Nieto et al., 2020; Landa et al., 2020; Kolivras et al., 2020). 
The lesions are described as Chilblains-like lesions, also known as perniosis (Landa et al., 2020). In a series 
testing of 63 patients, six testing were positive for COVID-19. The series showed that feet alone were 
affected most frequently (85.7%), followed by feet and hands (7%) together (Piccolo et al., 2020). Skin 
manifestations have been the focus of these reports, which have been described as presenting as rashes: 
petechial, erythematous, chilblains, and ischemic. In a study, data was collected from 88 hospitalized 
COVID-19 positive patients in Italy. Out of these, in 18 patients Cutaneous manifestations occurred, 
with the trunk cited as the primary involved area (Recalcati, 2020).  In a study from Wuhan, China, seven 
critical COVID-19 adult patients showed limb ischemia and gangrene in the feet and hands, which 
accounted for 21% of critically ill patients hospitalized at the same time (Zhang et al., 2020). It will take 
some time to fully understand the exact mortality rate of COVID-19. The crude mortality ratio (the 
number of reported deaths divided by the reported cases) calculated by the data we have so far is between 
3-4%, the infection mortality rate (the number of reported deaths divided by the number of infections) 
will be lower (WHO, 2020). 
13 Complications 
The pandemic, COVID-19 appears to be more severe in patients with underlying disease 
conditions like hypertension, cardiovascular disease, and diabetes (Guan et al., 2020) which means 
complications are more common in patients with comorbidities. Complications witnessed included acute 
lung injury, ARDS, shock, acute kidney injury, multiple organ failure and death (Hui et al., 2020). 
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14 Pathology 
 Depending upon the severity of disease four types of viral pneumonia can be observed. In minor 
pneumonia, minor serous exudation and minor fibrin exudation is seen. In case of mild pneumonia, 
pulmonary edema, large atypical pneumocytes, pneumocyte hyperplasia interstitial inflammation with 
lymphocytic infiltration and multinucleated giant cell formation is major finding. While diffuse alveolar 
damage (DAD) with diffuse alveolar exudates which is the cause of acute respiratory distress syndrome 
(ARDS) and severe hypoxemia is seen in severe pneumonia. While another type of pneumonia called 
healing pneumonia is also seen in which organization of exudates in alveolar cavities, 
plasmocytosis in BAL and pulmonary interstitial fibrosis are major findings (Giani et al., 2020). There is 
disseminated intravascular coagulation (DIC), thromboembolism and leukoerythroblastic reaction (Henry 
et al., 2020; Mitra, et al., 2020; Lillicrap et al., 2020).  
15 Diagnosis 
Diagnosis is done with the help of history, clinical signs and serological testing. A person with 
fever, sore throat and cough and having a history of travel to China or contact with patients with similar 
travel history or other areas of persistent local transmission is called a ‘suspect case’. However, cases may 
be asymptomatic or even without fever. A confirmed case is a suspect case with a positive molecular test 
is real-time reverse transcription polymerase chain reaction (rRT-PCR) is considered the standard method 
of testing. Diagnostic kits based on PCR are used in serodiagnosis of COVID-19 (Jin et al., 2020). 
Other laboratory investigations are usually non-specific. Other laboratory investigations are 
usually non specific. The chest X-ray (CXR) usually shows bilateral infiltrates but may be normal in early 
disease. The CT is more sensitive and specific than X-ray. The CT imaging generally shows infiltrates, 
ground glass opacities and sub segmental consolidation (Huang et al., 2020, Jin et al., 2020). It is also 
abnormal in asymptomatic patients/ patients with no clinical evidence of lower respiratory tract 
involvement. In fact, in suspect cases with negative molecular diagnosis, abnormal CT scans have been 
used to diagnose COVID-19 (Huang et al., 2020). There is usually lymphopenia with lymphocytic count < 
1000 in patients of COVID-19. The ESR and CRP are usually elevated while pro-calcitonin level is 
normal. Platelet count is usually normal or mildly low. The ALT/AST level, D-dimer level, creatinine 
level, CPK level, LDH level and pro-thrombin time elevation also has been reported (Henry et al., 2020). 
Moreover, it is also reported that elevated values of lactate dehydrogenase (LDH) and bilirubin is 
frequently associated with decreased hemoglobin concentration in patients with severe and fatal COVID-
19 (Henry et al., 2020). Moreover, ICU patients showed higher plasma levels of IL-2, IL-7, IL-10, IP10, 
GSCF, MCP1, MIP1A, and TNF-α than non-ICU patients. Also, initial plasma IL-1β, IL-1Rα, IL-7, IL-8, 
IL-9, IL-10, basic FGF, GCSF, GMCSF, IFNγ, IP10, MCP1, MIP1A, MIP1B, PDGF, TNF-α, and 
VEGF were found to be higher in 2019-nCoV-infected patients as compared to healthy controls (Huang 
et al., 2020). 
16 Differential Diagnosis 
The most common symptoms being reported are fever, dry cough or chest tightness and 
dyspnoea. Thus, they are indistinguishable from other respiratory infections. Hence the differential 
diagnosis of COVID-19 should be done with all types of respiratory viral infections like influenza, 
parainfluenza, respiratory syncytial virus (RSV), adenovirus, human metapneumovirus, atypical organisms 
(mycoplasma, chlamydia) and bacterial infections. Through routine lab tests, it is not possible to 
differentiate COVID-19 from these infections clinically. Therefore, here travel history i.e., a history of 
travel to China or contact with patients with similar travel history or other areas of persistent local 
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transmission becomes important (Jin et al., 2020). Then, the serodiagnosis via PCR is confirmatory (Jin et 
al., 2020) 
17 Treatment 
Since, it is a viral disease Treatment is essentially supportive and symptomatic. There are no 
medicines that have been shown to prevent or cure the disease while some traditional, western or home 
remedies may provide comfort and alleviate symptoms of mild COVID-19. Self-medication with any 
medicines, including antibiotics, as a prevention or cure for COVID-19 has not been recommended by 
WHO. However, both western and traditional medicines are undergoing clinical trials. For development 
of medicines and vaccines to prevent and treat COVID-19 WHO is coordinating efforts (WHO, 2020). 
Antibiotics do not work against viruses as they are effective only on bacterial infections. Therefore, 
Antibiotics should not be used as a means of prevention or treatment of COVID-19. To prevent or treat 
secondary bacterial infections which can be a complication of COVID-19 in severely ill patients, 
physicians will sometimes prescribe antibiotics. They should only be used on prescription of a physician 
to treat a bacterial infection (WHO, 2020). Antibiotics and antifungal are required only if co-infections are 
suspected or proven. The role of corticosteroids is yet unproven while WHO and current international 
consensus opposes their use. However, in COVID-19 ARDS, Chinese guidelines do recommend short 
term therapy with low-to-moderate dose corticosteroids (Russell et al., 2020; Zhao et al., 2020). In the 
Chinese guidelines, recommendations about using traditional Chinese herbs also find place (Zhao et al., 
2020). In hypoxic patients, provision of oxygen through nasal prongs, face mask, non-invasive ventilation 
or high flow nasal cannula (HFNC) is indicated. Mechanical ventilation and even extra corporeal 
membrane oxygen support may be needed. In patients with complication of acute renal injury, renal 
replacement therapy may be needed. Several drugs including lopinavir-ritonavir, remdesivir, 
hydroxychloroquine, and azithromycin have been tested in clinical trials (Cao et. al., 2020; Gautret et. al., 
2020; Zhou et. al., 2020) but none of them have been proven to be a definite therapy. 
18 Prevention and control 
Using proper preventive measures is the only effective way to break the chain of transmission of 
virus and to reduce the chances of getting infection. These includes staying at home, washing hands with 
soap and water often and for at least 20 seconds (Soap helps in inactivating the virus by destabilizing the 
lipid bilayer of virus) and if soap is not available apply an alcohol-based hand sanitizer with at least 60% 
alcohol, keeping distance from others, avoiding crowded places, practicing good respiratory hygiene, and 
avoiding touching the nose, eyes or mouth with unwashed hands. Along with following hygienic measures 
strictly one should boost up its natural immunity to lessen the chances of getting infection. The best way 
to protect others and yourself is practicing hand and respiratory hygiene is very important at all times. 
One should follow social distancing. If you have been in close contact with a person with COVID-19, 
you may get infection. Close contact means that you have been in a distance of less than 1 metre from 
those who have the disease. In these cases, it is best to stay at home. However, if you live in an area in 
which malaria or dengue fever is prevalent then it is important that you should not ignore symptoms of 
fever. Seek for medical help as soon as possible. And when you attend the health facility, if possible, wear 
a mask and keep at least 1 meter distance from other people and avoid touching surfaces with your hands. 
Help the child stick to this advice if it is a child who is sick. But if you do not live in malaria or dengue 
fever prevalent area, then if you feel sick, even with very mild symptoms like fever and headache, you 
must self-isolate yourself. And in condition in which you don’t even think that you have been exposed to 
COVID-19 but develop symptoms, then self-isolate and monitor yourself because in the early stages of 
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the disease when you just have mild symptoms you are more likely to infect others, therefore you must go 
for early self-isolation. If you do not have symptoms but previously you have been exposed to an infected 
person then self-quarantine for 14 days. In COVID-19 confirmed case and even after symptoms have 
disappeared; isolate yourself for 14 days as a precautionary measure because it is not yet known exactly 
that after recovery from the disease, for how long people remain infectious (WHO, 2020). On self-
isolation, follow national advice. One should use mask only if a person is coughing or sneezing or when 
one is taking care of someone with a suspected infection (WHO, 2020). Several countries like China, 
Spain, have recommended that healthy individuals wear face masks or cloth face coverings at least in 
certain public settings.  
19 Conclusion 
The COVID-19 is a fast spreading pandemic disease of major public health concern. The virus is 
mutating with time as well as the clinical presentation of disease is also changing with new upcoming 
cases. The virus was initially thought to involve only respiratory system but gradually with subsequent 
researches it is found that this disease not only involves respiratory system but also involve vascular 
system, nervous system, digestive system as well as cutaneous system. Its clinical signs vary, ranging from 
asymptomatic state to acute respiratory distress syndrome and multi organ dysfunction. Since, it’s a viral 
disease so only symptomatic treatment and supportive therapy is the option. Till now, no vaccine has 
been developed against COVID-19. So, prevention is the only way to protect ourselves. One should 
strictly follow all the preventive measures as directed by WHO and CDC and along with this, one should 
boost up its natural immunity to lessen the chances of getting infection, then only we shall be able to 
overcome this situation. 
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